Global Point of Care Diagnostics Market Expected to Reach USD 71 Billion in 2027
By LabMedica International staff writers Posted on 22 Aug 2021 |
Illustration
The global point of care diagnostics market is estimated to register a CAGR of 11.8% from 2019-2027 and grow from USD 26.60 billion in 2018 to USD 70.89 billion in 2027, driven by the introduction of new point-of-care testing (POCT) products that are aimed at delivering inexpensive care at facilities located at the closest-possible distances from the patients’ location.
These are the latest findings of a market research study by The Insight Partners (Pune, India), a market research & consulting firm.
POCT plays a critical role in the diagnosis, treatment, and prevention of infectious diseases. POC testing can be used to detect several major pathogens, including malarial parasites; human immunodeficiency virus (HIV); human papillomavirus (HPV); dengue, Ebola, and Zika viruses; and Mycobacterium tuberculosis (TB bacteria). To narrow down the diagnostic time, companies are developing POC test kits and reagents. The number of POCT has steadily increased over the last 40 years since its widespread introduction. The market growth is likely to continue with the help of the introduction of new products in the market aimed at delivering inexpensive care at the facilities located at the closest-possible distances from the patients’ location. New technologies or products are being refined and improved to deliver easier-to-use devices with incremental improvements in analytical performance.
Based on product, the global point of care diagnostics market was led by the glucose monitoring products segment in 2018 with the largest share. This segment is also expected to dominate the market until 2027 owing to the increase in the number of diabetic patients. However, the infectious disease testing products market is expected to grow at a significant rate during the forecast period. Moreover, infectious disease rapid test kits are widely available for a wide variety of prophlogistic pathogen targets, including bacterial, viral, fungal, protozoan, and other disease agents.
The global point of care diagnostics market has witnessed various organic as well as inorganic developments during recent years, including growth strategies such as approvals, collaborations, and partnerships. Geographically, Asia Pacific is the fastest growing point of care diagnostics market and is expected to be a significant revenue contributor during the forecast period. The region has witnessed several technological advancements in the field of healthcare with the incorporation of point of care diagnostics for increasing the efficiency of treatments. Additionally, there is growing interest among international players in China and India, government support in countries such as China, and improving healthcare infrastructure. Hence, players in the Asia Pacific point of care diagnostics market have huge potential for growth during the forecast period.
Related Links:
The Insight Partners
These are the latest findings of a market research study by The Insight Partners (Pune, India), a market research & consulting firm.
POCT plays a critical role in the diagnosis, treatment, and prevention of infectious diseases. POC testing can be used to detect several major pathogens, including malarial parasites; human immunodeficiency virus (HIV); human papillomavirus (HPV); dengue, Ebola, and Zika viruses; and Mycobacterium tuberculosis (TB bacteria). To narrow down the diagnostic time, companies are developing POC test kits and reagents. The number of POCT has steadily increased over the last 40 years since its widespread introduction. The market growth is likely to continue with the help of the introduction of new products in the market aimed at delivering inexpensive care at the facilities located at the closest-possible distances from the patients’ location. New technologies or products are being refined and improved to deliver easier-to-use devices with incremental improvements in analytical performance.
Based on product, the global point of care diagnostics market was led by the glucose monitoring products segment in 2018 with the largest share. This segment is also expected to dominate the market until 2027 owing to the increase in the number of diabetic patients. However, the infectious disease testing products market is expected to grow at a significant rate during the forecast period. Moreover, infectious disease rapid test kits are widely available for a wide variety of prophlogistic pathogen targets, including bacterial, viral, fungal, protozoan, and other disease agents.
The global point of care diagnostics market has witnessed various organic as well as inorganic developments during recent years, including growth strategies such as approvals, collaborations, and partnerships. Geographically, Asia Pacific is the fastest growing point of care diagnostics market and is expected to be a significant revenue contributor during the forecast period. The region has witnessed several technological advancements in the field of healthcare with the incorporation of point of care diagnostics for increasing the efficiency of treatments. Additionally, there is growing interest among international players in China and India, government support in countries such as China, and improving healthcare infrastructure. Hence, players in the Asia Pacific point of care diagnostics market have huge potential for growth during the forecast period.
Related Links:
The Insight Partners
Latest Industry News
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance
- Roche Acquires LumiraDx's Point of Care Technology for USD 295 Million
- Bruker Acquires IVD Manufacturer ELITech Group and Cell Imaging Company Phasefocus